Appendix 2 - Amendments to Claims

32. (Amended) A method of reducing the incidence of mortality associated with chronic congestive heart failure in a patient with impaired cardiac function and concomitant reduced exercise tolerance, comprising [sorally] orally administering to said patient between about 30 and about 300 milligrams of hydralazine hydrochloride per day, and at least one of (i) between about 20 and about 200 milligrams of isosorbide dinitrate, per day, and (ii) between about 10 and about 120 milligrams of isosorbide mononitrate, per day wherein the improvement comprises administering the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate to a black patient.

Cancel claims 39-41 and 50, without prejudice.

51. (New) The method of claim 32, wherein the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate are administered orally.

52. (New) The method of claim 51, wherein the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate are orally administered in the form of a solid dose.

53. (New) The method of claim 52, wherein the solid dose is in the form of a tablet or a capsule.

54. (New) The method of claim 53, wherein the capsule is in the form of a sustained release capsule.

55. (New) The method of claim 54, wherein the tablet is in the form of a sublingual tablet, a sustained-release tablet or a chewable tablet.

56. (New) The method of claim 32, wherein the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate are administered to the black patient as components of the same composition.

57. (New) The method of claim 32, wherein the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate are administered to the black patient as separate components.

58. (New) The method of claim 57, wherein the hydralazine hydrochloride and the at least one of isosorbide dinitrate and isosorbide mononitrate are administered to the black patient as separate components at about the same time.